The stock of Gyre Therapeutics Inc (GYRE) has gone down by -13.64% for the week, with a -18.42% drop in the past month and a 12.05% rise in the past quarter. The volatility ratio for the week is 9.42%, and the volatility levels for the past 30 days are 7.97% for GYRE. The simple moving average for the past 20 days is -14.64% for GYRE’s stock, with a 1.73% simple moving average for the past 200 days.
Is It Worth Investing in Gyre Therapeutics Inc (NASDAQ: GYRE) Right Now?
The 36-month beta value for GYRE is also noteworthy at 2.08. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GYRE is 13.94M, and at present, short sellers hold a 1.30% of that float. The average trading volume of GYRE on May 02, 2024 was 78.61K shares.
GYRE) stock’s latest price update
Gyre Therapeutics Inc (NASDAQ: GYRE)’s stock price has gone decline by -11.15 in comparison to its previous close of 15.60, however, the company has experienced a -13.64% decrease in its stock price over the last five trading days. The Motley Fool reported 2024-02-07 that Sigma Lithium, despite its vast reserves, faces challenges as lithium prices plummet, making its stock’s steep drop a cautionary tale. Hut 8 and Cipher Mining may be promising bets on a Bitcoin turnaround in the long run, but they may not survive the trip.
Analysts’ Opinion of GYRE
Many brokerage firms have already submitted their reports for GYRE stocks, with Stephens repeating the rating for GYRE by listing it as a “Overweight.” The predicted price for GYRE in the upcoming period, according to Stephens is $19 based on the research report published on April 29, 2021 of the previous year 2021.
Piper Sandler, on the other hand, stated in their research note that they expect to see GYRE reach a price target of $15. The rating they have provided for GYRE stocks is “Overweight” according to the report published on February 10th, 2021.
Raymond James gave a rating of “Outperform” to GYRE, setting the target price at $20 in the report published on May 21st of the previous year.
GYRE Trading at -21.41% from the 50-Day Moving Average
After a stumble in the market that brought GYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.41% of loss for the given period.
Volatility was left at 7.97%, however, over the last 30 days, the volatility rate increased by 9.42%, as shares sank -19.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.45% lower at present.
During the last 5 trading sessions, GYRE fell by -13.64%, which changed the moving average for the period of 200-days by +125.86% in comparison to the 20-day moving average, which settled at $16.07. In addition, Gyre Therapeutics Inc saw -46.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GYRE starting from USMAN NASSIM, who sale 20,000 shares at the price of $16.15 back on Apr 01 ’24. After this action, USMAN NASSIM now owns 1,636 shares of Gyre Therapeutics Inc, valued at $323,000 using the latest closing price.
USMAN NASSIM, the Director of Gyre Therapeutics Inc, sale 20,000 shares at $17.26 during a trade that took place back on Mar 15 ’24, which means that USMAN NASSIM is holding 1,636 shares at $345,200 based on the most recent closing price.
Stock Fundamentals for GYRE
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.97 for the gross margin
The net margin for Gyre Therapeutics Inc stands at -0.84. The total capital return value is set at -0.02. Equity return is now at value -269.01, with -215.90 for asset returns.
Based on Gyre Therapeutics Inc (GYRE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -39.58. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 17.93.
Currently, EBITDA for the company is 116.03 million with net debt to EBITDA at 3.03. When we switch over and look at the enterprise to sales, we see a ratio of 10.34. The receivables turnover for the company is 7.34for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In summary, Gyre Therapeutics Inc (GYRE) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
